Citi Upgrades Rigel Pharmaceuticals (RIGL) to Buy
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $45.89 +1.41%
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
5 Buy, 8 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Citi upgraded Rigel Pharmaceuticals (NASDAQ: RIGL) from Neutral to Buy with a price target of $13.00.
For an analyst ratings summary and ratings history on Rigel Pharmaceuticals click here. For more ratings news on Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $9.35 yesterday.
For an analyst ratings summary and ratings history on Rigel Pharmaceuticals click here. For more ratings news on Rigel Pharmaceuticals click here.
Shares of Rigel Pharmaceuticals closed at $9.35 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
- Bloom Burton & Co. Upgrades Aurinia Pharmaceuticals (AUPH) to Buy (1)
- Deutsche Bank Upgrades Target Hospitality (TH) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
